+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Excessive Daytime Sleepiness (EDS) - Market Insight, Epidemiology and Market Forecast -2032

  • ID: 5238588
  • Report
  • January 2022
  • Region: Global
  • 205 Pages
  • DelveInsight

FEATURED COMPANIES

  • Avadel Pharmaceutical
  • Axsome Therapeutic
  • Bioprojet Pharma
  • Harmony Biosciences
  • Jazz Pharmaceuticals
  • NLS Pharma Ltd
This "Excessive Daytime Sleepiness (EDS)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Excessive Daytime Sleepiness (EDS), historical and forecasted epidemiology as well as the Excessive Daytime Sleepiness (EDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Excessive Daytime Sleepiness (EDS) market report provides current treatment practices, emerging drugs, Excessive Daytime Sleepiness (EDS) market share of the individual therapies, current and forecasted Excessive Daytime Sleepiness (EDS) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Excessive Daytime Sleepiness (EDS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Excessive Daytime Sleepiness (EDS) Disease Understanding and Treatment Algorithm


The Excessive Daytime Sleepiness (EDS) market report gives a thorough understanding of the Excessive Daytime Sleepiness (EDS) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis


This segment of the report covers the detailed diagnostic methods or tests for Excessive Daytime Sleepiness (EDS).

Treatment


It covers the details of conventional and current medical therapies available in the Excessive Daytime Sleepiness (EDS) market for the treatment of the condition. It also provides Excessive Daytime Sleepiness (EDS) treatment algorithms and guidelines in the United States, Europe, and Japan.

Excessive Daytime Sleepiness (EDS) Epidemiology


The Excessive Daytime Sleepiness (EDS) epidemiology division provide insights about historical and current Excessive Daytime Sleepiness (EDS) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted Excessive Daytime Sleepiness (EDS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Excessive Daytime Sleepiness (EDS) Epidemiology


The epidemiology segment also provides the Excessive Daytime Sleepiness (EDS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Excessive Daytime Sleepiness (EDS) Drug Chapters


Drug chapter segment of the Excessive Daytime Sleepiness (EDS) report encloses the detailed analysis of Excessive Daytime Sleepiness (EDS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Excessive Daytime Sleepiness (EDS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs


The report provides the details of the marketed product available for Excessive Daytime Sleepiness (EDS) treatment.

Excessive Daytime Sleepiness (EDS) Emerging Drugs


The report provides the details of the emerging therapies under the late and mid-stage of development for Excessive Daytime Sleepiness (EDS) treatment.

Excessive Daytime Sleepiness (EDS) Market Outlook


The Excessive Daytime Sleepiness (EDS) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Excessive Daytime Sleepiness (EDS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Excessive Daytime Sleepiness (EDS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Excessive Daytime Sleepiness (EDS) market in 7MM is expected to change in the study period 2019-2032.

Key Findings


This section includes a glimpse of the Excessive Daytime Sleepiness (EDS) market in 7MM.

The United States Market Outlook


This section provides the total Excessive Daytime Sleepiness (EDS) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook


The total Excessive Daytime Sleepiness (EDS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook


The total Excessive Daytime Sleepiness (EDS) market size and market size by therapies in Japan is also mentioned.

Excessive Daytime Sleepiness (EDS) Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness (EDS) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Excessive Daytime Sleepiness (EDS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Excessive Daytime Sleepiness (EDS) Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Excessive Daytime Sleepiness (EDS) key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Excessive Daytime Sleepiness (EDS) emerging therapies.

Reimbursement Scenario in Excessive Daytime Sleepiness (EDS)


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views


To keep up with current market trends, we take KOLs and SME's opinion working in Excessive Daytime Sleepiness (EDS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Excessive Daytime Sleepiness (EDS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs Competitive and Market Intelligence analysis of the Excessive Daytime Sleepiness (EDS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Excessive Daytime Sleepiness (EDS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Excessive Daytime Sleepiness (EDS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Excessive Daytime Sleepiness (EDS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Excessive Daytime Sleepiness (EDS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Excessive Daytime Sleepiness (EDS) market

Report Highlights

  • In the coming years, Excessive Daytime Sleepiness (EDS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Excessive Daytime Sleepiness (EDS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Excessive Daytime Sleepiness (EDS). Launch of emerging therapies will significantly impact the Excessive Daytime Sleepiness (EDS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Excessive Daytime Sleepiness (EDS)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Excessive Daytime Sleepiness (EDS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Excessive Daytime Sleepiness (EDS) Pipeline Analysis
  • Excessive Daytime Sleepiness (EDS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Excessive Daytime Sleepiness (EDS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Excessive Daytime Sleepiness (EDS) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Excessive Daytime Sleepiness (EDS) Report Assessment


Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Excessive Daytime Sleepiness (EDS) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Excessive Daytime Sleepiness (EDS) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Excessive Daytime Sleepiness (EDS) market size during the forecast period (2019-2032)?
  • At what CAGR, the Excessive Daytime Sleepiness (EDS) market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Excessive Daytime Sleepiness (EDS) market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Excessive Daytime Sleepiness (EDS) market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Excessive Daytime Sleepiness (EDS)?
  • What is the historical Excessive Daytime Sleepiness (EDS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Excessive Daytime Sleepiness (EDS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Excessive Daytime Sleepiness (EDS)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Excessive Daytime Sleepiness (EDS) during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Excessive Daytime Sleepiness (EDS) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Excessive Daytime Sleepiness (EDS) in the USA, Europe, and Japan?
  • What are the Excessive Daytime Sleepiness (EDS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Excessive Daytime Sleepiness (EDS)?
  • How many therapies are developed by each company for Excessive Daytime Sleepiness (EDS) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Excessive Daytime Sleepiness (EDS) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Excessive Daytime Sleepiness (EDS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Excessive Daytime Sleepiness (EDS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Excessive Daytime Sleepiness (EDS)?
  • What are the global historical and forecasted market of Excessive Daytime Sleepiness (EDS)?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Excessive Daytime Sleepiness (EDS) market
  • To understand the future market competition in the Excessive Daytime Sleepiness (EDS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Excessive Daytime Sleepiness (EDS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Excessive Daytime Sleepiness (EDS) market
  • To understand the future market competition in the Excessive Daytime Sleepiness (EDS) market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Avadel Pharmaceutical
  • Axsome Therapeutic
  • Bioprojet Pharma
  • Harmony Biosciences
  • Jazz Pharmaceuticals
  • NLS Pharma Ltd

1 Key Insights2 Report Introduction
3 Excessive Daytime Sleepiness Market Overview at a Glance
3.1 Market Share (%) Distribution of Excessive Daytime Sleepiness in 2019
3.2 Market Share (%) Distribution of Excessive Daytime Sleepiness in 2032
4 Excessive Daytime Sleepiness Market: Future Perspective5 Executive Summary of Excessive Daytime Sleepiness6 Key Events
7 Excessive Daytime Sleepiness: Disease Background and Overview
7.1. Introduction
7.2. Causes of Excessive Daytime Sleepiness
7.3. Symptoms of Excessive Daytime Sleepiness
7.4. Classification
7.5. Diagnosis
7.5.1. Diagnostic Algorithm
7.5.2. Diagnosis Guidelines
7.6. Treatment and Management of Excessive Daytime Sleepiness
7.6.1. Treatment Algorithm
7.6.2. American Academy of Sleep Medicine Clinical Practice Guideline
8 Epidemiology and Patient Population
8.1. Key Findings
8.2. Epidemiology Methodology
8.3. Assumptions and Rationale: 7MM
8.3.1. The United States
8.3.2. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
8.3.2.1. Germany
8.3.2.2. France
8.3.2.3. Italy
8.3.2.4. Spain
8.3.2.5. The United Kingdom
8.3.3. Japan
8.4. Total Diagnosed Prevalent Population of Excessive Daytime Sleepiness in the 7MM
8.5. The United States
8.5.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the US
8.5.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the US
8.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
8.6.1. Germany
8.6.1.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Germany
8.6.1.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Germany
8.6.2. France
8.6.2.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in France
8.6.2.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in France
8.6.3. Italy
8.6.3.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Italy
8.6.3.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Italy
8.6.4. Spain
8.6.4.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Spain
8.6.4.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Spain
8.6.5. The United Kingdom
8.6.5.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the UK
8.6.5.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the UK
8.7. Japan
8.7.1. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Japan
8.7.2. Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Japan
9 Patient Journey
10 Marketed drugs:
10.1. Key Competitors
10.2. Wakix/ Ozawade (Pitolisant): Bioprojet Pharma/ Harmony Biosciences
10.2.1. Drug Description
10.2.2. Regulatory Milestones
10.2.3. Other Development Activities
10.2.4. Clinical Development
10.2.5. Clinical Trials Information
10.2.6. Safety and Efficacy
10.2.7. Product Profile
10.3. Sunosi (Solriamfetol): Jazz Pharmaceuticals
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Other Development Activities
10.3.4. Clinical Development
10.3.5. Clinical Trials Information
10.3.6. Safety and Efficacy
10.3.7. Product Profile
10.4. Xyrem (Sodium oxybate): Jazz Pharmaceuticals
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Other Development Activities
10.4.4. Clinical Development
10.4.5. Clinical Trials Information
10.4.6. Safety and Efficacy
10.4.7. Product Profile
10.5. Xywav (calcium, magnesium, potassium, and sodium oxybates): Jazz Pharmaceuticals
10.5.1. Drug Description
10.5.2. Regulatory Milestones
10.5.3. Other Development Activities
10.5.4. Clinical Development
10.5.5. Clinical Trials Information
10.5.6. Safety and Efficacy
10.5.7. Product Profile
11 Emerging Drugs
11.1. Key Cross Competition
11.2. FT218 (Sodium Oxybate): Avadel Pharmaceutical
11.2.1. Product Description
11.2.2. Other Development Activities
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.2.7. Analysts’ Views
11.3. AXS-12 (Reboxetine): Axsome Therapeutic
11.3.1. Product Description
11.3.2. Other Development Activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.3.7. Analysts’ Views
11.4. THN102 (Flecainide and Modafinil): Theranexus
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development
11.4.4. Clinical Trials Information
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.4.7. Analysts’ Views
11.5. Samelisant (SUVN-G3031): Suven Life Sciences
11.5.1. Product Description
11.5.2. Other Developmental Activities
11.5.3. Clinical Development
11.5.4. Clinical Trials Information
11.5.5. Safety and Efficacy
11.5.6. Product Profile
11.6. Quilience (Mazindol Extended-release/NLS-2): NLS Pharma Ltd
11.6.1. Product Description
11.6.2. Other Developmental Activities
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Product Profile
11.6.6. Analysts’ Views
11.7. XW10172: XWPharma
11.7.1. Product Description
11.7.2. Clinical Development
11.7.3. Clinical Trials Information
11.7.4. Safety and Efficacy
11.7.5. Product Profile
11.7.6. Analysts’ Views
11.8. TAK-994: Takeda Pharmaceutical
11.8.1. Product Description
11.8.2. Other Developmental Activities
11.8.3. Clinical Development
11.8.4. Clinical Trials Information
11.8.5. Product Profile
11.8.6. Analysts’ Views
12 Excessive Daytime Sleepiness: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Methodology
12.3. Market Size of Excessive Daytime Sleepiness in the 7MM
12.4. Market Size of Excessive Daytime Sleepiness by Therapies in the 7MM
12.5. Potential of Current and Emerging Therapies
12.6. Key Market Forecast Assumptions
12.7. Attribute Analysis
12.8. Market Outlook
12.9. Market Size of Excessive Daytime Sleepiness in the United States
12.9.1. Total Market Size of Excessive Daytime Sleepiness
12.9.2. Market Size of Excessive Daytime Sleepiness by Therapies
12.10. Market Size of Excessive Daytime Sleepiness in the EU-5
12.10.1. Germany
12.10.1.1. Total Market Size of Excessive Daytime Sleepiness
12.10.1.2. Market Size of Excessive Daytime Sleepiness by Therapies
12.10.2. France
12.10.2.1. Total Market Size of Excessive Daytime Sleepiness
12.10.2.2. Market Size of Excessive Daytime Sleepiness by Therapies
12.10.3. Italy
12.10.3.1. Total Market Size of Excessive Daytime Sleepiness
12.10.3.2. Market Size of Excessive Daytime Sleepiness by Therapies
12.10.4. Spain
12.10.4.1. Total Market Size of Excessive Daytime Sleepiness
12.10.4.2. Market Size of Excessive Daytime Sleepiness by Therapies
12.10.5. The United Kingdom
12.10.5.1. Total Market Size of Excessive Daytime Sleepiness
12.10.5.2. Market Size of Excessive Daytime Sleepiness by Therapies
12.11. Market Size of Excessive Daytime Sleepiness in Japan
12.11.1. Total Market Size of Excessive Daytime Sleepiness
12.11.2. Market Size of Excessive Daytime Sleepiness by Therapies
13 Key Opinion Leaders’ Views14 Market Drivers15 Market Barriers16 SWOT Analysis17 Unmet Needs18 Reimbursement and Market Access
19 Appendix
19.1. Bibliography
19.2. Report Methodology
20 Capabilities21 Disclaimer22 About the Publisher
List of Tables
Table 1 Summary of Excessive Daytime Sleepiness Market and Epidemiology (2019-2032)
Table 2 Key Events
Table 3 Common Causes or Contributors to Excessive Daytime Sleepiness
Table 4 ESS Scores
Table 5 Diagnostic Criteria for Narcolepsy Types 1 and 2 (Adapted from ICSD-3)
Table 6 Diagnostic Criteria for Idiopathic Hypersomnia (adapted from ICSD-3)
Table 7 Current Pharmacologic Treatment of Excessive Daytime Sleepiness Associated with Narcolepsy
Table 8 American Academy of Sleep Medicine Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnolence (1/3)
Table 9 American Academy of Sleep Medicine Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnolence (2/3)
Table 10 American Academy of Sleep Medicine Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnolence (3/3)
Table 11 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the 7MM, in ‘000’ (2019-2032)
Table 12
Table 13 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the US, in ‘000’ (2019-2032)
Table 14 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the US, in ‘000’ (2019-2032)
Table 15 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in EU-5, in ‘000’ (2019-2032)
Table 16 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in EU-5, in ‘000’ (2019-2032)
Table 17 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Germany, in ‘000’ (2019-2032)
Table 18 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Germany, in ‘000’ (2019-2032)
Table 19 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in France, in ‘000’ (2019-2032)
Table 20 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in France, in ‘000’ (2019-2032)
Table 21 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Italy, in ‘000’ (2019-2032)
Table 22 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Italy, in ‘000’ (2019-2032)
Table 23 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Spain, in ‘000’ (2019-2032)
Table 24 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Spain, in ‘000’ (2019-2032)
Table 25 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the UK, in ‘000’ (2019-2032)
Table 26 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the UK, in ‘000’ (2019-2032)
Table 27 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Japan, in ‘000’ (2019-2032)
Table 28 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the Japan, in ‘000’ (2019-2032)
Table 29 Comparison of Marketed Drugs Under Development
Table 30 Wakix (Pitolisant), Clinical Trial Description, 2022 (1/3)
Table 31 Wakix (Pitolisant), Clinical Trial Description, 2022 (2/3)
Table 32 Wakix (Pitolisant), Clinical Trial Description, 2022 (3/3)
Table 33 Highlights of Clinical trials
Table 34 Sunosi, Clinical Trial Description, 2022 (1/2)
Table 35 Sunosi, Clinical Trial Description, 2022 (2/2)
Table 36 Efficacy Results for Maintenance of Wakefulness Test (minutes) in Patients With Narcolepsy (Study 1) and OSA (Study 2)
Table 37 Efficacy Results for Epworth Sleepiness Scale in Patients With Narcolepsy (Study 1) and OSA (Study 2)
Table 38 Efficacy Results from Randomized Withdrawal Studies in Patients With Narcolepsy and OSA in Studies 3 and 4
Table 39 Xyrem, Clinical Trial Description, 2022
Table 40 Median Number of Cataplexy Attacks in Trials N1 and N2
Table 41 Change from Baseline in Daytime Sleepiness Score (Epworth Sleepiness Scale) at Week 8 in Trial N3 (Range 0-24)
Table 42 The Proportion of Patients with a Very Much or Much Improved Clinical Global Impression of Change in Daytime and Nighttime Symptoms in Trial N3
Table 43 Change in Baseline in the Maintenance of Wakefulness Test Score (in minutes) at Week 8 in Trial N4
Table 44 Number of Weekly Cataplexy Attacks and Epworth Sleepiness Scale (Child and Adolescent) Score (Trial N5)
Table 45 Clinical Global Impression of Change (CGIc) for Cataplexy Severity and Narcolepsy Overall (Trial N5)
Table 46 Xywav, Clinical Trial Description, 2022
Table 47 Mean and Median Number of Weekly Cataplexy Attacks and Epworth Sleepiness Scale (ESS)
Table 48 Number of Weekly Cataplexy Attacks and Epworth Sleepiness Scale (Child and Adolescent) Score
Table 49 Clinical Global Impression of Change (CGIc) for Cataplexy Severity and Narcolepsy Overall
Table 50 Comparison of Emerging Drugs Under Development (1/3)
Table 51 Comparison of Emerging Drugs Under Development (2/3)
Table 52 Comparison of Emerging Drugs Under Development (3/3)
Table 53 FT218, Clinical Trial Description, 2022
Table 54 AXS-12, Clinical Trial Description, 2022
Table 55 THN102, Clinical Trial Description, 2022
Table 56 Samelisant, Clinical Trial Description, 2022
Table 57 Quilience, Clinical Trial Description, 2022
Table 58 XW10172, Clinical Trial Description, 2022
Table 59 TAK-994 , Clinical Trial Description, 2022
Table 60 Market Size of Excessive Daytime Sleepiness in the 7MM, in USD Million (2019-2032)
Table 61 Market Size of Excessive Daytime Sleepiness by Therapies in the 7MM, in USD Million (2019-2032)
Table 62 Key Market Forecast Assumptions for FT218 (for EDS in Narcolepsy)
Table 63 Key Market Forecast Assumptions for Xywav (for EDS in Narcolepsy)
Table 64 Key Market Forecast Assumptions for AXS-12 (for EDS in Narcolepsy)
Table 65 Key Market Forecast Assumptions for Ozawade (for EDS in obstructive sleep apneoa)
Table 66 Key Market Forecast Assumptions for Xywav (for EDS in Idiopathic Hypersomnia)
Table 67 Key Market Forecast Assumptions for THN102 (for EDS in Parkinson’s disease)
Table 68 The United States Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Table 69 Market Size of Excessive Daytime Sleepiness by Therapies in the US, in USD Million (2019-2032)
Table 70 EU-5 Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Table 71 EU-5 Market Size of Excessive Daytime Sleepiness by Therapies, in USD Million (2019-2032)
Table 72 Germany Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Table 73 Market Size of Excessive Daytime Sleepiness by Therapies in Germany, in USD Million (2019-2032)
Table 74 France Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Table 75 Market Size of Excessive Daytime Sleepiness by Therapies in France, in USD Million (2019-2032)
Table 76 Italy Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Table 77 Market Size of Excessive Daytime Sleepiness by Therapies in Italy, in USD Million (2019-2032)
Table 78 Spain Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Table 79 Market Size of Excessive Daytime Sleepiness by Therapies in Spain, in USD Million (2019-2032)
Table 80 The United Kingdom Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Table 81 Market Size of Excessive Daytime Sleepiness by Therapies in the UK, in USD Million (2019-2032)
Table 82 Market Size of Excessive Daytime Sleepiness in Japan, in USD Million (2019-2032)
List of Figures
Figure 1 How EDS is Different from Fatigue?
Figure 2 Causes of Excessive Daytime Sleepiness
Figure 3 Symptoms of Excessive Daytime Sleepiness
Figure 4 Suggested Clinical Algorithm for the Diagnosis of Suspected OSA, Narcolepsy, or Other Sleep Disorders Based on Symptoms of Excessive Daytime Sleepiness
Figure 5 Clinical Approach in the Diagnosis of Excessive Daytime Sleepiness
Figure 6 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the 7MM, in ‘000’ (2019-2032)
Figure 7 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the US, in ‘000’ (2019-2032)
Figure 8 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the US, in ‘000’ (2019-2032)
Figure 9 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in EU-5, in ‘000’ (2019-2032)
Figure 10 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in EU-5, in ‘000’ (2019-2032)
Figure 11 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Germany, in ‘000’ (2019-2032)
Figure 12 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Germany, in ‘000’ (2019-2032)
Figure 13 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in France, in ‘000’ (2019-2032)
Figure 14 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in France, in ‘000’ (2019-2032)
Figure 15 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Italy, in ‘000’ (2019-2032)
Figure 16 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Italy, in ‘000’ (2019-2032)
Figure 17 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Spain, in ‘000’ (2019-2032)
Figure 18 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in Spain, in ‘000’ (2019-2032)
Figure 19 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in the UK, in ‘000’ (2019-2032)
Figure 20 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the UK, in ‘000’ (2019-2032)
Figure 21 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Japan, in ‘000’ (2019-2032)
Figure 22 Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders in the Japan, in ‘000’ (2019-2032)
Figure 23 Diagnostic and Treatment Approach for Excessive Daytime Sleepiness
Figure 24 Market Size of Excessive Daytime Sleepiness in the 7MM, in USD Million (2019-2032)
Figure 25 Market Size of Excessive Daytime Sleepiness by Therapies in the 7MM, in USD Million (2019-2032)
Figure 26 Key Market Forecast Assumptions for FT218 (for EDS in Narcolepsy)
Figure 27 Key Market Forecast Assumptions for Xywav (for EDS in Narcolepsy)
Figure 28 Key Market Forecast Assumptions for AXS-12 (for EDS in Narcolepsy)
Figure 29 Key Market Forecast Assumptions for Ozawade (for EDS in obstructive sleep apneoa)
Figure 30 Key Market Forecast Assumptions for Xywav (for EDS in Idiopathic Hypersomnia)
Figure 31 Key Market Forecast Assumptions for THN102 (for EDS in Parkinson’s disease)
Figure 32 The United States Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Figure 33 Market Size of Excessive Daytime Sleepiness by Therapies in the US, in USD Million (2019-2032)
Figure 34 EU-5 Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Figure 35 EU-5 Market Size of Excessive Daytime Sleepiness by Therapies, in USD Million (2019-2032)
Figure 36 Germany Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Figure 37 Market Size of Excessive Daytime Sleepiness by Therapies in Germany, in USD Million (2019-2032)
Figure 38 France Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Figure 39 Market Size of Excessive Daytime Sleepiness by Therapies in France, in USD Million (2019-2032)
Figure 40 Italy Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Figure 41 Market Size of Excessive Daytime Sleepiness by Therapies in Italy, in USD Million (2019-2032)
Figure 42 Spain Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Figure 43 Market Size of Excessive Daytime Sleepiness by Therapies in Spain, in USD Million (2019-2032)
Figure 44 The United Kingdom Market Size of Excessive Daytime Sleepiness in USD Million (2019-2032)
Figure 45 Market Size of Excessive Daytime Sleepiness by Therapies in the UK, in USD Million (2019-2032)
Figure 46 Market Size of Excessive Daytime Sleepiness in Japan, in USD Million (2019-2032)
Figure 47 Market Size of Excessive Daytime Sleepiness by Therapies in Japan, in USD Million (2019-2032)
Figure 48 Market Drivers
Figure 49 Market Barriers
Figure 50 SWOT Analysis
Figure 51 Unmet Needs
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bioprojet Pharma
  • Harmony Biosciences
  • Jazz Pharmaceuticals
  • Avadel Pharmaceutical
  • Axsome Therapeutic
  • Theranexus
  • Suven Life Sciences
  • NLS Pharma Ltd
  • XWPharma
  • Takeda Pharmaceutical
Note: Product cover images may vary from those shown